Moderna (MRNA) rose 20% pre-market after the company and Merck announced their melanoma skin cancer vaccine met its primary endpoint in a large-scale trial.
Jin1008/19, 05:52 PM
Related assets
Coming up for MRNA
Explore next
Latest MRNA news
Jin1010/23, 05:33 AM
Jin1010/23, 03:02 AM
Jin1010/23, 12:41 AM